Second Thoughts About Clozapine as a Treatment for Neuroleptic-Induced Akathisia
J Clin Psychiatry 1998;59(4):195-195 [letter]
© Copyright 2015 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Sir: Recently, Spivak et al. published an article in the Journal titled “Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.” The issue of finding an effective treatment for chronic treatment-resistant extrapyramidal side effects and akathisia is of considerable clinical importance. Various authors have proposed that clozapine may be useful in treating such patients based on case reports and open studies.